Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127158051 | 12715805 | 1 | I | 20160831 | 20160901 | 20160906 | 20160906 | PER | US-PFIZER INC-2016416612 | PFIZER | 42.00 | YR | M | Y | 55.00000 | KG | 20160906 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127158051 | 12715805 | 1 | PS | IRINOTECAN HCL | IRINOTECAN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 202 MG, ONCE EVERY 2 WEEKS | Y | N46577 | 20571 | 202 | MG | SOLUTION FOR INFUSION | |||||
| 127158051 | 12715805 | 2 | C | DOCUSATE | DOCUSATE | 1 | 0 | ||||||||||||
| 127158051 | 12715805 | 3 | C | HYDROMORPHONE | HYDROMORPHONE | 1 | 0 | ||||||||||||
| 127158051 | 12715805 | 4 | C | MAGNESIUM | MAGNESIUM | 1 | 400 MG, 2X/DAY | 0 | 400 | MG | BID | ||||||||
| 127158051 | 12715805 | 5 | C | BENADRYL | DIPHENHYDRAMINE HYDROCHLORIDE | 1 | 50 MG, UNK | 0 | 50 | MG | |||||||||
| 127158051 | 12715805 | 6 | C | TYLENOL | ACETAMINOPHEN | 1 | 650 MG, UNK | 0 | 650 | MG | |||||||||
| 127158051 | 12715805 | 7 | C | PALONOSETRON | PALONOSETRON | 1 | Intravenous (not otherwise specified) | 0.25 MG, UNK | 0 | .25 | MG | ||||||||
| 127158051 | 12715805 | 8 | C | PALONOSETRON | PALONOSETRON | 1 | 0 | ||||||||||||
| 127158051 | 12715805 | 9 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | Intravenous (not otherwise specified) | 10 MG, UNK | 0 | 10 | MG | ||||||||
| 127158051 | 12715805 | 10 | C | DEXAMETHASONE. | DEXAMETHASONE | 1 | 0 | ||||||||||||
| 127158051 | 12715805 | 11 | C | MAGNESIUM SULFATE. | MAGNESIUM SULFATE | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 127158051 | 12715805 | 12 | C | CETUXIMAB | CETUXIMAB | 1 | 835 MG, UNK | 0 | 835 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127158051 | 12715805 | 1 | Colon cancer |
| 127158051 | 12715805 | 2 | Constipation |
| 127158051 | 12715805 | 3 | Pain |
| 127158051 | 12715805 | 6 | Premedication |
| 127158051 | 12715805 | 7 | Nausea |
| 127158051 | 12715805 | 8 | Vomiting |
| 127158051 | 12715805 | 9 | Nausea |
| 127158051 | 12715805 | 10 | Vomiting |
| 127158051 | 12715805 | 11 | Hypomagnesaemia |
| 127158051 | 12715805 | 12 | Colon cancer |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127158051 | 12715805 | Diarrhoea | |
| 127158051 | 12715805 | Oesophageal spasm | |
| 127158051 | 12715805 | Speech disorder | |
| 127158051 | 12715805 | Vestibular disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127158051 | 12715805 | 1 | 20160831 | 0 |